WallStSmart

The Allstate Corporation (ALL)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Allstate Corporation generates 2017% more annual revenue ($68.17B vs $3.22B). ALL leads profitability with a 17.8% profit margin vs 16.9%. ALL appears more attractively valued with a PEG of 2.62. ALL earns a higher WallStSmart Score of 77/100 (B+).

ALL

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 8.0Value: 5.7Quality: 6.5
Piotroski: 5/9

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ALL.

WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALL6 strengths · Avg: 9.3/10
P/E RatioValuation
4.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
45.2%10/10

Every $100 of equity generates 45 in profit

EPS GrowthGrowth
338.4%10/10

Earnings expanding 338.4% YoY

Market CapQuality
$54.87B9/10

Large-cap with strong market position

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

ALL2 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.0%4/10

3.0% revenue growth

PEG RatioValuation
2.622/10

Expensive relative to growth rate

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ALL

The strongest argument for ALL centers on P/E Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.8% and operating margin at 19.0%.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : ALL

The primary concerns for ALL are Revenue Growth, PEG Ratio.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

ALL profiles as a value stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.17 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

ALL generates stronger free cash flow (3.5B), providing more financial flexibility.

Bottom Line

ALL scores higher overall (77/100 vs 67/100), backed by strong 17.8% margins. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Allstate Corporation

FINANCIAL SERVICES · INSURANCE - PROPERTY & CASUALTY · USA

The Allstate Corporation is an American insurance company, headquartered in Northfield Township, Illinois.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?